Short Interest Summary: CV SCIENCES INCORPORATED (OTCMKTS:CVSI)’s Trend Unknown, Especially After Increased Shorts

November 30, 2016 - By Dolores Ford   ·   0 Comments

Short Interest Summary: CV SCIENCES INCORPORATED (OTCMKTS:CVSI)’s Trend Unknown, Especially After Increased Shorts

The stock of CV SCIENCES INCORPORATED (OTCMKTS:CVSI) registered an increase of 590.56% in short interest. CVSI’s total short interest was 307,300 shares in November as published by FINRA. Its up 590.56% from 44,500 shares, reported previously. With 3.65 million shares average volume, it will take short sellers 0 days to cover their CVSI’s short positions. About 530,748 shares traded hands. CV Sciences Inc (OTCMKTS:CVSI) has declined 43.14% since April 27, 2016 and is downtrending. It has underperformed by 48.36% the S&P500.

CV Sciences, Inc. is a life science company. The company has a market cap of $16.48 million. The Firm operates in two divisions: specialty pharmaceuticals and consumer products. It currently has negative earnings. The Company’s specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol across several therapeutic areas.

CVSI Company Profile

CV Sciences, Inc., incorporated on July 26, 2013, is a life science company. The Firm operates in two divisions: specialty pharmaceuticals and consumer products. The Company’s specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol (CBD) across several therapeutic areas. The consumer product business segment is focused on manufacturing, marketing and selling plant CBD products to a range of market sectors.

Another recent and important CV Sciences Inc (OTCMKTS:CVSI) news was published by Marketwired.com which published an article titled: “CV Sciences, Inc. Issues Letter to Shareholders” on September 27, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>